Ranibizumab
- PDF / 169,253 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 2 Downloads / 178 Views
1 S
Ranibizumab Subconjunctival haemorrhage and off-label use: 4 case reports
In a retrospective study of preterm infants, who were admitted to the Neonatal Intensive Care Unit and Intermediate Care Unit at KAMC, Riyadh, Saudi Arabia from July 2012 to December 2016, four preterm infants including 2 female and 2 male infants were described, who developed subconjunctival haemorrhage during off-label treatment with ranibizumab. The preterm infants, who had retinopathy of prematurity received off-label treatment with a single intravitreal injection of ranibizumab 0.3mg. Intravitreal injections were performed under proxymetacaine [proparacaine] after installation of povidone iodine. The gestational age of infants was in the range of 24–28 weeks and their body weights at birth were between 935 and 2550g. All the four infants developed subconjunctival haemorrhage secondary to ranibizumab therapy [time to reaction onsets and outcomes not stated]. Aldebasi T, et al. Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity. Medical Principles and Practice 28: 526-532, No. 6, Nov 2019. Available from: URL: http://doi.org/10.1159/000500310
0114-9954/20/1788-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803448859
Reactions 25 Jan 2020 No. 1788
Data Loading...
